Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine

dc.contributor.authorYakubogullari N.
dc.contributor.authorCoven F.O.
dc.contributor.authorCebi N.
dc.contributor.authorCoven F.
dc.contributor.authorCoven N.
dc.contributor.authorGenc R.
dc.contributor.authorBedir E.
dc.contributor.authorNalbantsoy A.
dc.date.accessioned2024-07-22T08:06:18Z
dc.date.available2024-07-22T08:06:18Z
dc.date.issued2021
dc.description.abstractAstragaloside VII (AST-VII), a major cycloartane saponin isolated from Turkish Astragalus species, turned out to be one of the most active metabolites demonstrating Th1/Th2 balanced immune response. As Quillaja saponins are extensively used in adjuvant systems, this study made an attempt to improve AST-VII based adjuvant systems by using different immunostimulatory/delivery agents (monophosphoryllipid A (MPL), Astragalus polysaccharide (APS) and squalene) and to induce cellular and humoral immune response against a viral vaccine. For this purpose, Newcastle Disease vaccine (NDV) was chosen as a model vaccine. Swiss albino mice were immunized subcutaneously with LaSota vaccines in the presence/absence of AST-VII or developed adjuvant systems. AST-VII administration both in live/inactivated LaSota vaccines induced neutralizing and NDV specific IgG, IgG1 and IgG2b antibodies response as well as IL-2 and IL-4 production. APS based delivery systems enhanced the production of neutralizing antibody and the minor augmentation of IFN-γ and IL-2 levels. Squalene emulsion (SE) alone or combined with AST-VII were effective in NDV restimulated splenocyte proliferation. As a conclusion, AST-VII and AST-VII containing adjuvant systems demonstrated Th1/Th2 balanced antibody and cellular immune responses in NDV vaccines. Thus, these systems could be developed as vaccine adjuvants in viral vaccines as alternative to saponin-based adjuvants. © 2021 International Alliance for Biological Standardization
dc.identifier.DOI-ID10.1016/j.biologicals.2021.01.005
dc.identifier.issn10451056
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13467
dc.language.isoEnglish
dc.publisherAcademic Press
dc.rightsAll Open Access; Green Open Access
dc.subjectAdjuvants, Immunologic
dc.subjectAnimals
dc.subjectAntibodies, Neutralizing
dc.subjectAntibodies, Viral
dc.subjectInterferon-gamma
dc.subjectInterleukin-2
dc.subjectMice
dc.subjectNewcastle Disease
dc.subjectSaponins
dc.subjectSqualene
dc.subjectVaccines, Attenuated
dc.subjectVaccines, Inactivated
dc.subjectViral Vaccines
dc.subjectastragaloside VII
dc.subjectbacterial polysaccharide
dc.subjectgamma interferon
dc.subjectimmunoglobulin G
dc.subjectimmunoglobulin G1
dc.subjectimmunoglobulin G2b
dc.subjectimmunostimulating agent
dc.subjectinterleukin 2
dc.subjectinterleukin 4
dc.subjectmonophosphoryllipid A
dc.subjectneutralizing antibody
dc.subjectNewcastle disease vaccine
dc.subjectsaponin
dc.subjectsqualene
dc.subjectunclassified drug
dc.subjectastragaloside VII
dc.subjectgamma interferon
dc.subjectimmunological adjuvant
dc.subjectinactivated vaccine
dc.subjectinterleukin 2
dc.subjectlive vaccine
dc.subjectneutralizing antibody
dc.subjectsaponin
dc.subjectsqualene
dc.subjectvirus antibody
dc.subjectvirus vaccine
dc.subjectanimal cell
dc.subjectantibody response
dc.subjectArticle
dc.subjectcell function
dc.subjectcell proliferation
dc.subjectcontrolled study
dc.subjectcytokine production
dc.subjectdrug design
dc.subjectdrug screening
dc.subjectemulsion
dc.subjectfemale
dc.subjecthemagglutination inhibition
dc.subjecthumoral immunity
dc.subjectimmune response
dc.subjectimmunization
dc.subjectmale
dc.subjectmouse
dc.subjectNewcastle disease
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectspleen cell
dc.subjectvirus neutralization
dc.subjectanimal
dc.subjectimmunology
dc.subjectNewcastle disease
dc.titleEvaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine
dc.typeArticle

Files